The bioequivalence of two clarithromycin tablets, the $Klaricid^{TM}$ (Ciba-Geigy Korea Ltd.) and the $Pylocin^{TM}$ (Kyungdong Pharmaceutical Co., Ltd.), was evaluated according to the Korean Guidelines for Bioequivalence Test (KGBT 1998). Sixteen healthy male volunteers ($20sim26$ years old) were randomly divided into two groups and a randomized $2 imes2$ cross-over study was employed. After one tablet containing 250 mg of clarithromycin was orally administered, blood sample was taken at predetermined time intervals, and the concentrations of clarithromycin in serum were determined using high-performance liquid chromatographic method with electrochemical detector. The pharmaco-kinetic parameters (area under the concentration-time curve: $AUC_t$, maximum concentration; $C_{max}$ and time to maximum concentration; $T_{max}$) were calculated and analysis of variance (ANOVA) was utilized for the statistical analysis of parameters. The results showed that the differences in $AUC_t,;C_{max};and;T_{max}$ between two tablets based on $Klaricid^{TM}$ tablet were $-0.22\%,;-0.48\%;and;-1.63\%$, respectively. The powers $(1-eta);for;AUC_t,;C_{max};and;T_{max};were;99.07\%,;88.15\%;and;99.99\%$, respectively. Detectable differences $(Delta);and;90\%$ confidence intervals ($alpha$=0.10) were all less than $pm20\%$ All the parameters above met the criteria of KGBT 1998, indicating that $Pylocin^{TM}$ tablet is bioequivalent to $Klaricid^{TM}$ tablet.